以下文章来源于吴晓波频道 ，作者巴九灵 吴晓波频道 . 这是财经作家吴晓波带领"巴九灵"们运营的知识平台，这里汇聚了400多万认可商业之美、崇尚自我奋斗、乐意奉献共享、拒绝屌丝文化的新中产。 健康意识觉醒。 作者 | 巴九灵 来源 | 吴晓波频道 （ID： wuxiaobopd ） "舌苔偏厚，体质寒湿，肝火旺，建议少吃辛辣、冰饮。" 下午时分，26岁的白领小陈对着手机摄像头伸出舌头，屏幕那端的AI医生瞬间给出了这样的反馈。 这不，最近巨头们如火如荼的闪购战，让不少人真切体验了一把奶茶自由。网络上，关于"冰箱塞满奶茶""两天九杯冲上头"的分享不 胜枚举，但也敲响了年轻人的身体警钟。 在"求医AI"前，小陈刚好收到了动态血糖仪APP弹出的"血糖飙升"警告。 图源：小红书 公开数据显示，中国咖啡消耗量近10年内增长了167%，消费者偏好带奶、带糖、带小料的花式咖啡；奶茶消费同样也是，超8成用户 一周消费2—3次，甚至高于3次，高频消费的同时还爱搭配软欧包食用。 当这样的"甜蜜轰炸"成为日常，直接催生了一个热词——咖啡病。 所谓"咖啡病"，不是医学术语，而是指一种新式"亚健康状态"，可以表现为心慌、头昏、疲惫、暴饮 ...

与社区居民共度美好时光。7月18日,齐鲁晚报·齐鲁壹点"漱玉平民杯"第十届社区文化节走进济南历下区 龙洞街道办事处财富花园社区,为市民带来便民服务和精彩演出。 文/片 刘桂斌 济南报道 欢乐是每场社区文化节不变的主题。下午五点半,文艺演出环节正式开始,小丑表演带动了全场的气氛,赢 得了现场居民的阵阵掌声。紧接着,魔术师亮相,空袋子里忽然抖出一把红包,又瞬间变出五彩丝巾,观众还 来不及眨眼,他已把掌声和惊叹声收入囊中。 社区文艺骨干轮番献艺:舒缓的太极扇与音乐喷泉交相辉映,青年合唱团的改编歌曲把现场气氛推向高潮, 压轴的集体舞更是带动全场观众一起挥动手机闪光灯,广场瞬间化作一片星海。居民宋女士抱着孙子感 慨:"不用出小区就能看演出,比在家看电视热闹多了!" 义诊＋流动办公桌 便民服务送到家门口 舞台东侧的蓝色帐篷同样人气高涨。漱玉平民大药房把"微型体检站"搬到现场,血压、血糖、骨密度检 测全部免费。专业工作人员一边操作仪器,一边叮嘱老人夏季饮食起居注意事项。 情景科普笑声不断 "反诈奶奶团"讲反诈 在泉城济南,活跃着一支平均年龄超67岁的"反诈奶奶团",从受骗者到反诈"明星",她们个个身怀"绝活",唱 歌、跳舞 ...

以下文章来源于吴晓波频道 ，作者巴九灵 吴晓波频道 . 这是财经作家吴晓波带领"巴九灵"们运营的知识平台，这里汇聚了400多万认可商业之美、崇尚自我奋 斗、乐意奉献共享、拒绝屌丝文化的新中产。 来源丨吴晓波 频道 （ID： wuxiaobopd ） 图源：小红书 当这样的"甜蜜轰炸"成为日常，直接催生了一个热词——咖啡病。 所谓"咖啡病"，不是医学术语，而是指一种新式"亚健康状态"，可以表现为心慌、头昏、疲惫、暴饮 暴食后的反弹焦虑，以及不请自来的体重飙升。 作者丨 钱汐汐、沈晓琴 编辑丨何梦飞 图源丨Midjourney "舌苔偏厚，体质寒湿，肝火旺，建议少吃辛辣、冰饮。" 下午时分，26岁的白领小陈对着手机摄像头伸出舌头，屏幕那端的AI医生瞬间给出了这样的反馈。 这不，最近巨头们如火如荼的闪购战，让不少人真切体验了一把奶茶自由。网络上，关于"冰箱塞满 奶茶""两天九杯冲上头"的分享不胜枚举，但也敲响了年轻人的身体警钟。 在"求医AI"前，小陈刚好收到了动态血糖仪APP弹出的"血糖飙升"警告。 公开数据显示，中国咖啡消耗量近10年内增长了167%，消费者偏好带奶、带糖、带小料的花式咖 啡；奶茶消费同样也是， ...

点击上图▲立即收听 " 18—35 岁年轻人的消费榜单前三位，分别是旅游、数码产品和保健养生。 " 文 / 巴九灵（微信公众号：吴晓波频道） "舌苔偏厚，体质寒湿，肝火旺，建议少吃辛辣、冰饮。" 下午时分，26岁的白领小陈对着手机摄像头伸出舌头，屏幕那端的AI医生瞬间给出了这样的反馈。 而看似戏谑的背后，实则是一种集体性的健康觉醒。 由国家统计局等发起的《中国美好生活大调查》显示，18—35岁年轻人的消费榜单前三位分别是旅游、数码产品和保健养生。另外根据知萌咨询 在今年3月的调研数据，Z世代平均每年在健康消费上的支出达到3250.7元。 这不，最近巨头们如火如荼的闪购战，让不少人真切体验了一把奶茶自由。网络上，关于"冰箱塞满奶茶""两天九杯冲上头"的分享不胜枚举，但也 敲响了年轻人的身体警钟。 在"求医AI"前，小陈刚好收到了动态血糖仪APP弹出的"血糖飙升"警告。 公开数据显示，中国咖啡消耗量近10年内增长了167%，消费者偏好带奶、带糖、带小料的花式咖啡；奶茶消费同样也是，超8成用户一周消费2— 3次，甚至高于3次，高频消费的同时还爱搭配软欧包食用。 当这样的"甜蜜轰炸"成为日常，直接催生了一个热词——咖 ...

Core Viewpoint - Abbott's strong performance in Q2 was driven by robust demand for continuous glucose monitoring systems, although the company's guidance fell short of market expectations, leading to a pre-market stock decline [1] Financial Performance - Adjusted Q2 earnings per share reached $1.26, slightly above the analyst consensus of $1.25 [1] - Total revenue for the quarter was $11.1 billion, exceeding market expectations of $11.07 billion [1] - The medical device segment, particularly diabetes and cardiovascular-related devices, reported sales of $5.37 billion, surpassing the expected $5.24 billion [1] - Sales of continuous glucose monitoring devices, including the FreeStyle Libre series and Lingo product line, surged 21.4% year-over-year to $1.9 billion [1] Future Outlook - For Q3, Abbott projects earnings per share between $1.28 and $1.32, below the market expectation of $1.34 [1] - The company has lowered its full-year earnings guidance to an adjusted range of $5.10 to $5.20 per share, down from the previous forecast of $5.05 to $5.25 [1] Strategic Developments - Abbott announced plans to build a new manufacturing facility in Georgia by 2028 to support its cardiovascular business, complementing previously announced projects in Illinois and Texas [2] - These initiatives aim to mitigate potential negative impacts from tariffs introduced by the Trump administration [2]

7月16日，三诺生物今日收盘22.43元，上涨1.08%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到39.58倍，总市值125.67亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入10.42亿元，同比2.76%；净利润7211.51万元， 同比-10.90%，销售毛利率48.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三诺生物39.5838.513.80125.67亿行业平均 51.8747.354.50108.06亿行业中值37.4837.062.5352.67亿1九安医疗10.8510.970.85183.07亿2英科医疗 12.0913.041.08191.07亿3新华医疗14.3613.311.1792.03亿4振德医疗15.4114.530.9855.95亿5山东药玻 15.4415.491.77146.06亿6奥美医疗15.7915.481.6257.06亿7康德莱16.2616.271.3535.03亿8奥泰生物 16.8417.751.3653.69亿9九强生物16.8915.712.0783.66亿10维力医疗17.2617.942.02 ...

Summary of the Conference Call on the Wearable Health Monitoring Devices Industry Industry Overview - The conference call focused on the **wearable health monitoring devices industry** in China, highlighting its rapid growth and potential to transition from a technological novelty to a necessity for the general public [1][2][3]. Key Points and Arguments 1. **Explosive Growth**: The wearable health monitoring devices industry is experiencing explosive growth, driven by several core factors [1]. 2. **Market Size Expansion**: The market size is expected to exceed **200 billion** yuan, indicating a significant expansion [1]. 3. **Key Growth Engines**: The industry must overcome three major challenges to achieve a transformation from a tech consumer product to a public health necessity [1]. 4. **Health Issues in the Workforce**: Increasing health issues among Chinese workers, with **90.5%** of employees facing sleep deprivation, are driving the industry's growth [3][4]. 5. **Aging Population and Chronic Diseases**: The acceleration of aging and the rising prevalence of chronic diseases are also significant drivers for the industry [4][5]. 6. **Product Evolution**: Non-invasive blood glucose monitors are evolving from mere health monitoring tools to becoming integral to health management systems connecting families with healthcare providers [5]. 7. **Market Growth Trajectory**: From **2020 to 2024**, the market size is projected to grow from **140 billion** yuan to **150 billion** yuan, despite short-term fluctuations due to economic conditions [5]. 8. **Differentiated Development Paths**: Consumer-grade products (e.g., smart bands, watches) and medical-grade products are developing along different paths [5][6]. 9. **Rapid Market Growth**: The market is expected to grow from **51.8 billion** yuan in 2020 to **116.6 billion** yuan by 2029, with products like Huawei Watch D receiving medical device certification [6]. 10. **Industry Structure**: The industry operates on a three-tier structure involving upstream suppliers, midstream manufacturers, and downstream sales channels [6][7]. 11. **Sensor Market Growth**: The sensor market is projected to grow at a **15%** compound annual growth rate, expected to exceed **500 billion** yuan by 2026 [6]. 12. **Market Share Dynamics**: The online and offline markets for wearable devices are showing a trend towards balance, with smartwatches dominating offline sales [7]. 13. **Consumer Market Dominance**: Major technology companies like Huawei, Apple, and Xiaomi dominate the consumer market, leveraging strong R&D capabilities [8]. 14. **Integration of Medical Functions**: Some medical companies are attempting to enter the consumer market, but face challenges in brand recognition and user perception [8]. 15. **Technological Advancements**: The industry is undergoing significant technological changes, with AI advancements expected to enhance device capabilities [9]. 16. **Healthcare Integration**: Wearable devices are becoming crucial nodes in remote healthcare systems, promoting a shift from disease-centered to health-centered paradigms [9][10]. 17. **Case Studies**: The strategies of key players like Huawei and medical device companies illustrate the competitive landscape and strategic choices within the industry [10]. Other Important Insights - The industry is supported by a comprehensive policy framework that includes technological innovation, standardization, and integration with healthcare [3]. - The evolution of wearable devices is not just a technological advancement but also a shift in healthcare paradigms, emphasizing preventive health management [9][10]. This summary encapsulates the key insights and developments discussed in the conference call regarding the wearable health monitoring devices industry, providing a comprehensive overview of its current state and future potential.

2025年7月14日， 九安医疗 （股票代码：002432）发布了2025年半年度业绩预告。 | 项目 | 本期报告 | 上年同期 | | --- | --- | --- | | 归属上市公司股东的净利润 | 盈利: 88,000 万元-98,000 万元 | 盈利: 60,175.95 万元 | | | 比上年同期增长:46.24%-62.86% | | | 扣除非经营性损益的净利润 | 盈利：86,000 万元-96,000 万元 | 盈利：69,754.62 万元 | | | 比上年同期增长:23.29%-37.63% | | | 基本每股收益 | 盈利: 2.0129 元/股-2.2416 元/股 | 盈利: 1.3788 元/股 | 根据公告，公司预计2025年上半年实现归属于上市公司股东的 净利润为8.8亿元至9.8亿元 ，同比 增长46.24%至62.86% ；扣非净利润预计为8.6亿元至9.6亿 元，同比增长 23.29%至37.63% ；基本每股收益预计为2.0129元/股至2.2416元/股。 iHealth蓝牙智能血压计 业绩增长原因 2025年一季度财报数据 2025年第一季度，九安医 ...

Key Points Summary of Kefu Medical Conference Call Company Overview - **Company**: Kefu Medical - **Industry**: Medical Devices Core Insights and Arguments 1. **Impact of Online Business Adjustments**: Kefu Medical's revenue and profit remained stable year-on-year in Q2 2025 despite adjustments in online business, with core product strategies proving effective [2][3][4] 2. **Product Performance**: The company reported strong market performance for its respiratory machines and dual glucose-uric acid test strips, with the latter achieving the highest sales in its category [3][4] 3. **New Product Launch**: A bone conduction hearing aid is set to launch in September 2025, developed in collaboration with Tencent to enhance product competitiveness [2][6] 4. **O2O Business Growth**: Rapid growth in the O2O restaurant business was noted, with expectations for the O2O medical device category to reach 6 billion this year [3][4] 5. **H Share Issuance**: Kefu Medical plans to issue H shares to support international expansion and acquisitions, with a focus on reducing dilution impact on A shares [2][5][9] 6. **Acquisition of Himala**: The acquisition of Himala, Hong Kong's largest medical device chain, aims to enhance market presence and product quality, with Himala generating approximately 200 million HKD in sales [2][8][19] 7. **International Strategy**: The company is targeting high-quality brands and channels in Europe and Southeast Asia for future acquisitions, leveraging China's competitive manufacturing capabilities [4][10][29] Additional Important Information 1. **Financial Performance**: Kefu Medical's overseas revenue is expected to exceed 100 million in H1 2025, with a projected total of over 300 million for the year, marking significant growth compared to previous years [4][13] 2. **Profit Margin Outlook**: The acquisition of Himala is anticipated to improve profit margins from 10% to over 16% through supplier adjustments and product restructuring [14][19] 3. **Market Dynamics**: The competitive landscape for blood glucose and rehabilitation products is intensifying, with ongoing price wars and innovation among major players [26] 4. **Sales Channel Performance**: Online sales accounted for nearly 70% of total sales in H1 2025, with Douyin showing the fastest growth among platforms [24][25] 5. **Future Growth Areas**: The company expects significant improvements in health monitoring categories, particularly in home testing and temperature measurement products [22][23] This summary encapsulates the key points discussed in the conference call, highlighting Kefu Medical's strategic initiatives, product performance, and market outlook.

Group 1: Company Performance - The overall operating status in Q2 remained stable, with strong growth in hearing aids, home testing reagents, dressings, and adult care products [2] - The self-developed ventilator achieved outstanding performance, ranking first in sales on Douyin, with industry-leading noise reduction and performance [3] - The blood glucose and uric acid integrated machine showcases a unique dual-testing technology, reducing user burden and medical costs [3] Group 2: Hong Kong Listing Rationale - The current national policy supports companies "going global," making the Hong Kong listing aligned with policy direction and beneficial for international development [4] - The Hong Kong market offers a high degree of internationalization, providing a quality financing platform for companies [4] - Establishing an H-share platform is a strategic move to enhance overseas business capabilities and improve cross-border M&A efficiency [4] Group 3: International Business Strategy - The company aims for internationalization through a combination of organic growth and acquisitions, continuously enhancing its overseas business layout [5] - Significant investments are being made in overseas markets, with local product development and registration efforts underway [5] - The company completed acquisitions of Huazhou and Ximan in the first half of the year, enhancing overseas business resources [5] Group 4: Acquisition Projects - Huazhou, established in 2002, is a leading manufacturer of pressure-sensitive adhesive products, with over 60% of its revenue from overseas [6] - Ximan, with nearly 40 years of experience, operates retail medical device centers and will help the company penetrate the Hong Kong market [7] - Future acquisitions will focus on companies that can enhance product lines or technical capabilities and those with established distribution networks or brand influence [7] Group 5: Hearing Aid Business Outlook - The hearing aid business is focused on improving operational quality and has seen some improvement in profitability [7] - The Chinese hearing aid market has significant growth potential but faces challenges such as low public awareness and usage rates [7] - The company plans to provide comprehensive services for hearing-impaired individuals, leveraging its core competitive advantage in personalized solutions [7]